KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) Operating Expenses (2016 - 2025)

Novartis Ag's Operating Expenses history spans 15 years, with the latest figure at -$6.2 billion for Q2 2025.

  • On a quarterly basis, Operating Expenses fell 13.03% to -$6.2 billion in Q2 2025 year-over-year; TTM through Mar 2026 was -$6.2 billion, a 61.87% increase, with the full-year FY2025 number at $24.4 billion, up 8.23% from a year prior.
  • Operating Expenses hit -$6.2 billion in Q2 2025 for Novartis Ag, up from -$10.7 billion in the prior quarter.
  • Over the last five years, Operating Expenses for NVS hit a ceiling of -$672.0 million in Q3 2022 and a floor of -$12.4 billion in Q2 2023.
  • Historically, Operating Expenses has averaged -$4.7 billion across 5 years, with a median of -$3.1 billion in 2021.
  • Biggest five-year swings in Operating Expenses: crashed 1273.07% in 2023 and later surged 56.16% in 2024.
  • Tracing NVS's Operating Expenses over 5 years: stood at -$808.0 million in 2021, then rose by 2.1% to -$791.0 million in 2022, then crashed by 1273.07% to -$10.9 billion in 2023, then grew by 1.31% to -$10.7 billion in 2024, then skyrocketed by 42.45% to -$6.2 billion in 2025.
  • Business Quant data shows Operating Expenses for NVS at -$6.2 billion in Q2 2025, -$10.7 billion in Q4 2024, and -$5.5 billion in Q2 2024.